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A B S T R A C T
Tortoises belonging to the Testudinidae family are infected by Testudinid herpesviruses. Testudinid herpesvirus
3 (TeHV-3) is considered the most pathogenic and aﬀects several tortoise species, particularly those from the
Testudo genus. As most species of this genus are endangered contribute to ecological concerns over this virus.
Here, we aimed to explore the rational development of an antiviral treatment against TeHV-3 using Hermann's
tortoise (Testudo hermanni) as a host model. Ten antiviral compounds were tested in cell culture for their toxicity
and their activity against TeHV-3. Eight compounds exhibited diﬀerent levels of activity against TeHV-3 with
either no or only minor cytotoxic eﬀects on cells. Next, eprociclovir (EPV, ciprovir) was selected for further
investigations in vivo. Its pharmacokinetic properties were investigated after a single sub-cutaneous adminis-
tration at 5 or 10mg/kg. Plasma concentrations remained above half maximal eﬀective concentration (EC50) for
2.2 and 4.4 h after administration at 5 and 10mg/kg, respectively. Finally, EPV toxicity was investigated after
administration at the dose of 10mg/kg, BID for seven consecutive days. As early as one day after initiation of the
treatment up to its end, EPV plasma concentration remained under the EC50. Apathy and anorexia developed
after 7 days. Biochemical and anatomopathological examinations revealed nephrotoxic eﬀects of EPV.
Altogether, these data suggest that EPV is not a suitable molecule for the treatment of TeHV-3. Further studies
are required to determine whether the other molecules identiﬁed here for their anti-TeHV-3 activity represent
potential candidates for the development of eﬃcacious treatments.
There are at least 60 species of tortoises in the Testudinidae family.
Herpesviruses have been isolated from most of these species, in both
healthy and sick subjects. These herpesviruses have been grouped into
four genotypes named as testudinid herpesvirus 1 to 4 (TeHV-1 to
TeHV-4) (Bicknese et al., 2010). Among these genotypes, TeHV-3 is the
most pathogenic and has been shown to aﬀect several tortoise species,
with those from the genus Testudo (e.g., Testudo hermanni) being the
most sensitive to infection (Bicknese et al., 2010; Martel et al., 2009).
The fact that these host species are also endangered contributes to
ecological concerns over TeHV-3.
The main clinical signs associated with TeHV-3 include nasal dis-
charge, rhinitis, conjunctivitis and diphtheritic plaques in the oral
cavity and oesophagus. Weight loss, cachexia, central nervous symp-
toms and death are associated with advanced stages of the disease.
Young tortoises are more susceptible to TeHV-3 disease than adults and
can express a mortality rate of up to 100% (Martel et al., 2009). To
date, treatments against TeHV-3 infection remain mainly symptomatic
and empiric. Etiological treatment based on acyclovir (ACV) (at 80mg/
kg) has been suggested in tortoises (Origgi, 2006; Wright, 2008).
However, neither the safety nor the eﬃcacy of this treatment has been
tested experimentally in tortoises (Marschang et al., 1997). Here, we
initiated the rational development of an antiviral treatment against
TeHV-3 using Hermann's tortoises (Testudo hermanni) as a host model.
First, ten antiviral compounds were tested in cell culture for their
toxicity and activity against TeHV-3 replication. In vitro antiviral mo-
lecule screening was performed in 96-well pates (BD Falcon, Franklin
Lakes, USA). Tortoise heart cells (TH-1, subline B1, ATCC CCL-50) were
seeded at the density of 1.5× 104 cells/well (Gandar et al., 2015). After
an incubation of 48 h, cells were inoculated with TeHV-3 at a multi-
plicity of infection of 0.2 PFU/cell and then overlaid with 200 μL per
well of Dulbecco's modiﬁed Eagle's medium supplemented with 5%
(vol/vol) foetal calf serum (Sigma-Aldrich, Overijse, Belgium) and the
molecules to be tested (at concentrations of 0, 0.4, 2, 10 and 50 μg/mL).
The following antiviral molecules kindly provided by Dr. J. Neyts
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(Katholieke Universiteit Leuven, Belgium) were tested: pencyclovir
(PCV), 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine (PMPDAP),
ACV, phosphonoformic acid (PFA), gancyclovir (GCV), eprociclovir
(EPV, previously known as ciprovir), adefovir (ADV), cidofovir (CDV),
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) and te-
nofovir (TFV). The proportion of cytopathogenic eﬀect on total surface
of each infected well was estimated 7 days post infection by macro-
scopic examination of the cell monolayer subdivided in 6 equivalent
parts. Eﬀective concentration (EC50) was calculated for each molecule
using the logarithmic interpolation method (Jin-Li et al., 2015) based
on 6 replicates. Statistical analyses of EC50 data were performed by
using the Wilcoxon nonparametric test. Value of P < .05 and P < .01
(*) were considered signiﬁcant. None of the compounds revealed cell
death at the doses tested (data not shown). However, abnormal aspects
of TH-1 cells consisting of cytoplasm densiﬁcation and shape mod-
iﬁcations were observed for ADV, CDV, PMEDAP and TFV at a con-
centration of 50 μg/mL suggesting a mild cytotoxicity. PCV and
PMPDAP did not inhibit TeHV-3 at the concentrations tested (data not
shown), and so were not included in Fig. 1A. The calculated EC50 of
each eﬃcacious molecules were as follows (in increasing order of ef-
ﬁcacy, mean ± SD): ACV=25.5 (± 4.5); PFA=15.9 (± 3.5);
GCV=7.5 (± 5.1); EPV=3.9 (± 0.7); ADV=3.2 (± 0.2);
CDV=1.3 (± 0.4); PMEDAP=0.6 (± 0.1); TFV=0.7 (± 0.1) μg/
mL. Mean EC50 values were all statistically diﬀerent from each other
(P < .05, Fig. 1A) with exception of EPV and ADV data (P= .0868).
EPV induced a complete inhibition of viral replication at 10.0 (± 0.7)
μg/mL.
Based on the in vitro results above (both toxicity on cells and in-
hibition of TeHV-3 replication), EPV was selected for further in vivo
investigations. All in vivo protocols described below were approved by
the Ethic Committee of the University of Liège (protocol n°1235). Five-
year old Hermann's tortoises (T. hermanni) (mean weight of
298.0 g,± 24.3) were kept individually as described elsewhere (Gandar
et al., 2015). Relative humidity was maintained at 60–70%. Lighting
was controlled automatically on standard 12 h light and 12 h dark cir-
cadian cycles, with an UVb light switched on during the 12 h light
period. The temperature of an infrared basking spot was regulated at
29 °C during the light period and 24 °C during the dark period, re-
spectively. A temperature gradient of approximately 6 °C was present in
the terrariums, with the basking spot being the warmest place. Fresh
water and vegetables were provided daily. Clinical examinations of
tortoises immediately prior to the experiments revealed that they were
clinically healthy. Experiments were preceded by an acclimatization
period of 2 weeks. To investigate the pharmacokinetic properties of EPV
in tortoises, a single administration of EPV at the dose of 5 (3 subjects)
or 10mg/kg (3 subjects) was performed by subcutaneous injections in
the forelimbs. One subject was injected with 0.9% NaCl as negative
control. Blood samples were collected from the jugular vein at 0, 0.5, 1,
2, 4, 8, 12, 24 and 48 h post injection. EPV plasma concentrations were
determined by high-performance liquid chromatography with the
modiﬁed pre-column derivatization method as previously described
(Iwayama et al., 1999). To investigate possible acute toxicity of the
molecule, complete blood counts and serum biochemical exams were
performed just before administration of EPV and 48 h post injection. At
the end of the experiment, all animals were euthanized and necropsied
according to conventional techniques and guidelines (Terrell and Stacy,
2007). Brain, spleen, lungs, kidneys, liver, and a portion of small in-
testine were ﬁxed in neutral buﬀered 10% formalin for histological
examination. EPV plasma concentrations were measurable in all treated
tortoises (Fig. 1B). Non-compartmental PK analysis were performed
using Phoenix WinNonlin® 8.0 (Certara, Princeton, USA) on individual
values. Theoretical sampling times were used for calculation of PK
parameters. Statistical analyses of time above EC50 were performed
with a Wilcoxon test. Cmax and half-life time (T1/2) means of the two
doses were compared using a Student's t-test. P values under 0.05 were
considered to be statistically signiﬁcant. For both dosages, Tmax was
reached after 30min and T1/2 was estimated at 1.58 (± 0.19) and 1.84
(± 0.23) hours at the dose of 5 and 10mg/kg, respectively. No sig-
niﬁcant diﬀerence was detected between the T1/2 of the two doses.
However, a signiﬁcant diﬀerence (P= .0467) was noticed between
durations above the EC50 with 2.2 (± 1.0) and 4.4 (± 1.4) hours at 5
and 10mg/kg, respectively. Haematology and biochemistry values
observed before and 48 h post injection were compared for each animal.
An increase in creatine phosphokinase (CPK) was observed. The value
observed 48 h after injection ranged from 15 to 156 fold the value
observed before the injection. Red blood cell count, white blood cell
count, total plasma proteins, albumin, globulins, calcium, phosphate
aspartate transaminase (AST) and uric acid (UA) were not aﬀected and
were in the normal range for the species (data not shown) (Andreani
et al., 2014). No gross lesions were noted at necropsy examination, also
histology of collected organs did not reveal lesions suggesting absence
of acute toxicity.
Next, we investigated the toxicity of an EPV regime consisting of a
daily subcutaneous injection at the dose of 10mg/kg (3 subjects) for
Fig. 1. (A) EC50 (μg/mL) of eight antiviral molecules tested against TeHV-3 in
TH-1 cell cultures. ACV: acyclovir; PFA: phosphonoformic acid; GCV: gancy-
clovir; EPV: eprociclovir; ADV: adefovir; CDV: cidofovir; PMEDAP: 9-(2-phos-
phonylmethoxyethyl)-2,6-diaminopurine; TFV: tenofovir. Data represent the
analysis of replicates (n=6). The mean of the 6 replicates± SD is presented
for each drug. (B) Pharmacokinetic and acute toxicity evaluation of EPV fol-
lowing a single subcutaneous administrations in Testudo hermanni. Mean plasma
concentration (μg/ml ± SD) after a single subcutaneous administration at
5 mg/kg (•, n= 3) and 10mg/kg (□, n= 3) of EPV. Maximal concentration
(Cmax), time-to-maximum (Tmax), time above EC50 (> EC50), half-life (T1/2)
and area under the curve (AUC) were determined for each concentration.
Horizontal dashed line represents the in vitro EC50 value of EPV.
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seven days (mean weight of 302.3 g,± 25.5). One subject was injected
with 0.9% NaCl as negative control. EPV plasma concentrations were
determined at the following time points: 1, 2, 3, 5, 7 and 14 days.
Complete blood counts and serum biochemical exams were performed
at day 0, 7 and 14 to investigate possible chronic toxicity of the mo-
lecule. EPV plasma concentrations remained under EC50 after day 1
(Fig. 2A). No accumulation eﬀect of the molecule was observed. In
addition, tortoises became anorectic and apathetic between days 7 and
9 after initiation of the treatment. Consistent with the results of the ﬁrst
experiment, an increase in CPK was observed in each tortoise at day 7
and 14. A similar increase was observed in the negative control in-
dicating that this parameter is likely inﬂuenced by the manipulations
performed (injection and/or blood collection). In all EPV treated ani-
mals, AST and UA values were increased in comparison with the normal
values for this species (Fig. 2B) (Andreani et al., 2014). Other
parameters were in the normal ranges. At necropsy, kidney pallor (light
tan) in all treated animals was noted. Histologic examination revealed a
loss of structure of the renal parenchyma with a heterophilic and
lymphocytic inﬁltration compatible with an acute interstitial nephritis
(Fig. 2C). The presence of hyaline casts in proximal and distal tubule
lumens with dilation of some distal tubules was also noticed. In the liver
parenchyma of treated tortoises, a heterophilic inﬁltration compatible
with a non-speciﬁc inﬂammation process was observed. Histological
examination of other organs did not reveal any abnormalities.
Etiological treatment of TeHV-3 infection with ACV (at 80mg/kg)
has been suggested in tortoises (Origgi, 2006; Wright, 2008). However,
neither the safety nor the eﬃcacy of this treatment has been tested
experimentally in tortoises (Marschang et al., 1997). Our EC50 results of
ACV (Fig. 1A) demonstrated that this molecule has a reduced activity
against TeHV-3 compared to other herpesviruses (Neyts et al., 1998).
These data suggest that ACV is unlikely to represent an eﬃcacious
treatment against TeHV-3. Based on our in vitro results, EPV, ADV, CDV,
PMEDAP and TFV appear all as potential candidates for TeHV-3 treat-
ment. Unfortunately, no studies are available on these molecules in
reptiles, similarly their toxicity and their pharmacokinetics in tortoises
are unknown. However, ADV, CDV and TFV are well known to be ne-
phrotoxic in long-term treatment in humans (Broekema and Dikkers,
2008; Gara et al., 2012; Lacy et al., 1998; Tourret et al., 2013; Vittecoq
et al., 1997). Also, PMEDAP has been revealed to be highly toxic in
pigeons (unpublished data). In the present study, we observed that
ADV, CDV, PMEDAP and TFV aﬀect the morphology of TH-1 culture
cells suggesting toxicity. Based on its safety and eﬃcacy proﬁle, we
selected EPV for in vivo study in tortoises.
The half-life of EPV in tortoises is shorter than that of ACV in turtles
(Terrapene carolina) (Allender et al., 2013). However, it is important to
note that EPV is a nucleoside analogue which accumulates in the cy-
toplasm of cells after its conversion into a triphosphate active form
(Jordheim et al., 2013). Consequently, plasma concentrations and half-
life time determination could give an underestimation of the in-
tracellular half-life of the molecule. However, the results obtained in
the present study in relation to EPV plasma concentration (Fig. 1. B)
and its toxicity (Fig. 2 B and C) do not support its use for the devel-
opment of a safe and eﬃcacious treatment against TeHV-3 under these
conditions.
In conclusion, the present study seeds the basis for the rational
development of an antiviral treatment against TeHV-3, which is con-
tributing to the population decline of endangered species of tortoises.
Furthermore, it also highlights the importance of taking into con-
sideration the physiology of this particular type of host, which is very
diﬀerent from that of the species in which candidate antiviral molecules
have been previously tested.
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